# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Thomas Jefferson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN005-SYN-TD
- Date: 1790-06-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Beaumont-Ruiz, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review, four weeks after starting propranolol. **S**

## History of present illness

Mr. Jefferson returns four weeks after starting propranolol 80 mg each evening. He felt a little tired in the first week, and that has passed; he has had no dizziness, wheeze or breathlessness on his walks. His diary shows 4 migraine days in the past four weeks, each treated with sumatriptan and naproxen; he was pain-free within two hours in three of the four attacks and back at work by midday. He used no other acute medicine, so his acute-medicine days total 4. The cold he had ten days ago has gone. His diary is missing three days during the cold. He has not yet seen the occupational therapist because of a waiting list, and writing remains slow; he has started using dictation for long reports. **S**

| Element | Detail |
|---|---|
| Propranolol | 80 mg each evening for four weeks; tiredness in the first week only |
| Migraine days | 4 in the past four weeks, from 13 before prevention |
| Acute medicine | Sumatriptan with naproxen on 4 days; pain-free at two hours in 3 of 4 |
| Cold | Resolved |
| Occupational therapy | Not yet seen; waiting list |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Tiredness of the first week has passed |
| Respiratory | Negative | No wheeze or breathlessness |
| Neurological | Positive | Four migraine attacks in four weeks; no new features |
| Musculoskeletal | Positive | Right wrist stiff and sore after long writing |

4 systems reviewed. **S**

## Current medications

- Naproxen 500 mg oral tablet, one tablet with food at the start of a headache, may repeat once after 12 hours; no more than two days a week **S**
- Metoclopramide 10 mg oral tablet, one tablet with the naproxen when a headache brings nausea; no more than two days a week **S**
- Sumatriptan 100 mg oral tablet, one tablet with naproxen early in a migraine attack, may repeat once after 2 hours; no more than two tablets a day and no more than nine days a month **S**
- Propranolol extended-release 120 mg oral capsule, one capsule each evening, for migraine prevention **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/74 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 76 kg; BMI 21.3 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 116/74, pulse 60 |
| Neurological | Normal |
| Musculoskeletal | Right wrist with reduced flexion and extension and a prominent ulnar head; finger joints swollen; grip weaker on the right |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Migraine without aura on propranolol** (G43.009). Propranolol 80 mg is well tolerated, with a pulse of 60 and blood pressure of 116/74. Migraine days are down from 13 to 4 in four weeks, but part of the fall is the natural end of the bout, and it is too early to judge the preventive. The triptan with naproxen works well. Acute medicine on 4 days, within the limits. The PHQ-9 planned four to six weeks after starting propranolol was not repeated today. **S**
   - Increase propranolol to 120 mg each evening.
   - Continue sumatriptan with naproxen as needed.
   - Three-month review with the MIDAS, HIT-6 and PHQ-9.
2. **Stiff right wrist after an old dislocation** (M25.631). Still waiting for occupational therapy. **S**
   - The clinic has booked a hand therapist with an earlier opening.
   - Dictation for long reports.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Red-flag screen (SNNOOP10): systemic signs, neurological signs, sudden or new pattern, onset after 50, positional or Valsalva features, papilledema, progressive course | Every visit | Completed today | No red flags |
| Survey | Headache diary: headache and migraine days, attack features, triggers | Every visit | Completed today | 4 migraine days in four weeks; three days missing during the cold |
| Medication safety | Acute-medicine days (medication overuse headache limits: triptan fewer than 10, NSAID fewer than 15 days a month) | Every visit | Completed today | Acute medicine on 4 days in four weeks |
| Medication safety | Acute treatment response (pain-free at two hours, return to work) | Every visit | Completed today | Pain-free at two hours in 3 of 4 attacks with sumatriptan and naproxen |
| Medication safety | Propranolol tolerability: pulse, blood pressure, tiredness, exercise tolerance, wheeze, cold hands, sleep | Four weeks after starting or changing the dose, then each visit | Completed today | Pulse 60, blood pressure 116/74; tiredness in the first week only; no wheeze; dose raised to 120 mg |
| Examination | Preventive efficacy (at least 50% fewer migraine days) | At two to three months on an adequate dose | Due | Four weeks on 80 mg; efficacy judged at the three-month review |
| Survey | Disability (MIDAS, recorded as its five items, and HIT-6) | At baseline and after about three months of prevention | Up to date | Repeat at three months |
| Survey | Mood (PHQ-9) and anxiety (GAD-7), including on a beta-blocker | At baseline, four to six weeks after starting a preventive that can affect mood, then at each review | Deferred | The PHQ-9 planned four to six weeks after starting propranolol was not repeated today. No harm is evident: he reports a steady mood and no low mood or loss of interest on direct questions. Corrective action: PHQ-2 at the preventive visit and PHQ-9 and GAD-7 at the three-month review |
| Imaging | Neuroimaging | Only for red flags or a change in pattern | Not indicated | No red flags or change in pattern |
| Self-management | Sleep, meals, caffeine and work-stress plan | Every visit | Completed today | Fixed wake time and regular lunch kept; walks most days |
| Referral | Occupational therapy visit for the right wrist and writing | Within four weeks of intake | Deferred | Not seen four weeks after intake because of a waiting list. No harm so far beyond continued slow writing, eased by dictation. Corrective action: the clinic booked a hand therapist with an earlier opening |

## Goal progress

- A two-week headache diary that allows a firm diagnosis. Outcome by 1790-05-21: Diary of 14 days kept; ICHD-3 criteria for migraine without aura met; no red flags. **S**
- Monthly migraine days reduced by at least half within three months of starting prevention. In progress; target 1790-08-13. **S**
- Acute medicine on no more than two days a week, so that medication overuse headache does not develop. In progress; target 1790-08-13. **S**
- Pain-free within two hours of acute treatment in most attacks. In progress; target 1790-08-13. **S**
- Lower headache-related disability. In progress; target 1790-08-13. **S**
- Write for longer without wrist pain. In progress; target 1790-08-13. **S**

## Medication changes

- Stopped: Propranolol extended-release 80 mg oral capsule, one capsule each evening, for migraine prevention **S**
- Started: Propranolol extended-release 120 mg oral capsule, one capsule each evening, for migraine prevention **S**

## Guideline basis

- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018), International Headache Society (Cephalalgia 2018;38(1):1-211)
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021), American Headache Society (Headache 2021;61(7):1021-1039)
- Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024), American Headache Society (Headache 2024;64(4):333-341)
- The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice (2019), American Headache Society (Headache 2019;59(1):1-18)
- Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians (2025), American College of Physicians (Annals of Internal Medicine 2025;178(4):571-578)
- Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians (2025), American College of Physicians (Annals of Internal Medicine 2025;178(3):426-433)
- Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013), American Headache Society (Headache 2013;53(10):1651-1659)
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Preventive visit in four weeks. Three-month review in eight weeks. Diary continued. **S**
- Next scheduled visit 1790-07-16: periodic adult preventive visit. **S**
